AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25088746 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased plasma levels of very long chain ceramide species
Number of subjects: 497
Study 25088746 — intervention group
Group type: COMPARATOR
Intervention: Normal albuminuria
Number of subjects: 497
Study 25088746 — intervention group
Group type: COMPARATOR
Intervention: Microalbuminuria
Number of subjects: 497
Study 25088746 — intervention group
Group type: COMPARATOR
Intervention: Macroalbuminuria
Number of subjects: 497
Study 23285923 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentolaminum group
Number of subjects: 360
Study 23285923 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate-phentolaminum group
Number of subjects: 360
Study 23285923 — intervention group
Group type: EXPERIMENTAL
Intervention: Anisodamine-phentolaminum group
Number of subjects: 360
Study 23285923 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 360
Study 19863842 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 807
Study 19863842 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 807
Study 19863842 — intervention group
Group type: EXPERIMENTAL
Intervention: Latent trajectory mixture models
Number of subjects: 807
Study 19863842 — intervention group
Group type: COMPARATOR
Intervention: Drop-out control
Number of subjects: 807
Study 18165405 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibulectomy
Number of subjects: 51
Study 18165405 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback
Number of subjects: 51
Study 18165405 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Number of subjects: 51
Study 18165405 — intervention group
Group type: COMPARATOR
Intervention: All treatments (Vestibulectomy, Biofeedback, Cognitive-behavioral therapy)
Number of subjects: 51
Study 16124946 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg
Number of subjects: 28
Study 12457076 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine
Number of subjects: 0
Study 11152036 — intervention group
Group type: EXPERIMENTAL
Intervention: Written questionnaire
Number of subjects: 700
Study 11152036 — intervention group
Group type: COMPARATOR
Intervention: Standardised face-to-face interview
Number of subjects: 700
Study 11152036 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods (questionnaire and interview)
Number of subjects: 700
Study 9404089 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitor group (drastic cleaning every three weeks)
Number of subjects: 30
Study 9404089 — intervention group
Group type: COMPARATOR
Intervention: Control group (insufficient cleaning)
Number of subjects: 30
Study 9404089 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitor group
Number of subjects: 30
Study 9404089 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 9404089 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 8504436 — intervention group
Group type: COMPARATOR
Intervention: Intravenous 4-aminopyridine (4-AP)
Number of subjects: 70
Study 8504436 — intervention group
Group type: COMPARATOR
Intervention: Oral 4-aminopyridine (4-AP) at maximum daily dosage of 0.5 mg/kg body weight, three times a day for 12 weeks
Number of subjects: 70
Study 3323291 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. pulsatile Gn‐RH at 2.5 micrograms/90 min (A; no. = 10)
Number of subjects: 10
Study 3323291 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. pulsatile Gn‐RH at 5 micrograms/90 min (B; no. = 13)
Number of subjects: 10
Study 3323291 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. pulsatile Gn‐RH at 10-12.5 micrograms/90 min (C; no. = 3)
Number of subjects: 10
Study 31047650 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) in ED
Number of subjects: 252
Study 31047650 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC) in ED
Number of subjects: 252
Study 31047650 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) in Pathology
Number of subjects: 252
Study 31047650 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC) in Pathology
Number of subjects: 252
Study 29103847 — intervention group
Group type: EXPERIMENTAL
Intervention: Left Atrial Appendage Closure (LAAC) with Watchman device
Number of subjects: 1114
Study 29103847 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 1114
Study 29103847 — intervention group
Group type: EXPERIMENTAL
Intervention: LAAC
Number of subjects: 1114
Study 26420970 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy (rabeprazole 20 mg and amoxicillin 1 g twice daily for 5 days, followed by rabeprazole 20 mg, clarithromycin 500 mg and metronidazole 500 mg twice daily for 5 days)
Number of subjects: 175
Study 26420970 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid therapy (rabeprazole 20 mg and amoxicillin 1 g for 7 days, followed by rabeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg twice daily for 7 days)
Number of subjects: 175
Study 23713295 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 60
Study 23713295 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 60
Study 21708034 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylsulfonylmethane (MSM) 1.125 grams 3 times daily for 12 weeks
Number of subjects: 49
Study 21708034 — intervention group
Group type: COMPARATOR
Intervention: Placebo 3 times daily for 12 weeks
Number of subjects: 49
Study 21708034 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylsulfonylmethane (MSM)
Number of subjects: 49
Study 18048863 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant tissue-type plasminogen activator
Number of subjects: 40
Study 16817081 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethacridine lactate (10 ml per gestational week, max 200 ml)
Number of subjects: 388
Study 16817081 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (200 microg intravaginally, followed by 100 microg oral every 4 hours for 24 hours)
Number of subjects: 388
Study 16817081 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethacridine lactate + Oxytocin (initial 6 mU/min, additional 6 mU/min every 20 min)
Number of subjects: 388
Study 16817081 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol + Oxytocin (administered similarly to group III)
Number of subjects: 388
Study 16817081 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin with misoprostol
Number of subjects: 388
Study 16817081 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 388
Study 12946886 — intervention group
Group type: EXPERIMENTAL
Intervention: QIDS-SR(16)
Number of subjects: 596
Study 12946886 — intervention group
Group type: EXPERIMENTAL
Intervention: IDS-SR(30)
Number of subjects: 596
Study 12946886 — intervention group
Group type: EXPERIMENTAL
Intervention: HAM-D(24)
Number of subjects: 596
Study 11302109 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg daily
Number of subjects: 4271
Study 11302109 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 4271
Study 9449936 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 0
Study 9449936 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 8363165 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified-fat (vegetable oil) mozzarella cheese product
Number of subjects: 26
Study 8363165 — intervention group
Group type: COMPARATOR
Intervention: Skim-milk mozzarella cheese
Number of subjects: 26
Study 31697817 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic platelet transfusion threshold of 25 × 10^9/L
Number of subjects: 653
Study 31697817 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic platelet transfusion threshold of 50 × 10^9/L
Number of subjects: 653
Study 30269148 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 51
Study 30269148 — intervention group
Group type: COMPARATOR
Intervention: Healthy Controls
Number of subjects: 51
Study 27072860 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 0
Study 27072860 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25191666 — intervention group
Group type: EXPERIMENTAL
Intervention: Adper Single Bond (SB) with cariogenic challenge (pH)
Number of subjects: 80
Study 25191666 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond (SE) with cariogenic challenge (pH)
Number of subjects: 80
Study 25191666 — intervention group
Group type: COMPARATOR
Intervention: Adper Single Bond (SB) with sound enamel (S)
Number of subjects: 80
Study 25191666 — intervention group
Group type: COMPARATOR
Intervention: Clearfil SE Bond (SE) with sound enamel (S)
Number of subjects: 80
Study 25191666 — intervention group
Group type: COMPARATOR
Intervention: Control (C) groups
Number of subjects: 80
Study 25191666 — intervention group
Group type: COMPARATOR
Intervention: Permanent groups (PERM)
Number of subjects: 80
Study 21994233 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab plus methotrexate (5 mg/kg at weeks 0, 2, 6, and 14 plus 15 mg/week methotrexate)
Number of subjects: 115
Study 21994233 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab plus methotrexate
Number of subjects: 115
Study 21994233 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate alone (15 mg/week)
Number of subjects: 115
Study 21994233 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate alone
Number of subjects: 115
Study 21161650 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous bilateral tubeless PCNL
Number of subjects: 99
Study 21161650 — intervention group
Group type: COMPARATOR
Intervention: Staged tubeless PCNL
Number of subjects: 99
Study 17561989 — intervention group
Group type: EXPERIMENTAL
Intervention: Drotrecogin alpha activated
Number of subjects: 0
Study 17561989 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15583700 — intervention group
Group type: EXPERIMENTAL
Intervention: sibutramine (10 mg/day)
Number of subjects: 80
Study 15583700 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 80
Study 12397571 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma history in IDCM cases
Number of subjects: 197
Study 12397571 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma duration in IDCM cases
Number of subjects: 197
Study 12397571 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-agonist use
Number of subjects: 197
Study 12397571 — intervention group
Group type: COMPARATOR
Intervention: Control group asthma history
Number of subjects: 197
Study 10534551 — intervention group
Group type: EXPERIMENTAL
Intervention: iloprost (1 ng/kg/min in 6 h i.v. infusion, for 5 consecutive days, 1 week per month)
Number of subjects: 20
Study 10534551 — intervention group
Group type: EXPERIMENTAL
Intervention: low-dose oral cyclosporin A (2.5 mg/kg/day) associated with iloprost
Number of subjects: 20
Study 7567390 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory radio interference during training sessions for 4 weeks, 3 hours per week.
Number of subjects: 0
Study 7567390 — intervention group
Group type: EXPERIMENTAL
Intervention: Interference training condition
Number of subjects: 0
Study 7567390 — intervention group
Group type: COMPARATOR
Intervention: Standard training
Number of subjects: 0
Study 2141289 — intervention group
Group type: EXPERIMENTAL
Intervention: Orchiectomy plus dexamethasone 0.5 mg in the morning and 0.3 mg at night
Number of subjects: 60
Study 2141289 — intervention group
Group type: COMPARATOR
Intervention: Orchiectomy plus cyproterone acetate 100 mg 3 times per day
Number of subjects: 60
Study 484522 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridoxine 2 mg
Number of subjects: 22
Study 484522 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridoxine 100 mg
Number of subjects: 22
Study 484522 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 484522 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridoxine 100 mg (retreatment)
Number of subjects: 22
Study 484522 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurements of flexion and pinch strength
Number of subjects: 22
Study 484522 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyography
Number of subjects: 22
Study 31570495 — intervention group
Group type: EXPERIMENTAL
Intervention: Programmed intermittent bolus (PIB) delivery of local anesthetic (10 mL of ropivacaine 0.2% every 2 hours)
Number of subjects: 60
Study 31570495 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion (CI) (5 mL/hour) of local anesthetic
Number of subjects: 60
Study 31570495 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CI and PIB regimens
Number of subjects: 60
Study 30373650 — intervention group
Group type: EXPERIMENTAL
Intervention: aPDT with Bixa orellana extract and LED light (Valo Cordless Ultradent®)
Number of subjects: 39
Study 30373650 — intervention group
Group type: COMPARATOR
Intervention: Tongue scraping
Number of subjects: 39
Study 30373650 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of tongue scraping and aPDT with Bixa orellana extract
Number of subjects: 39
Study 26488941 — intervention group
Group type: EXPERIMENTAL
Intervention: Human chorionic gonadotropin (HCG)
Number of subjects: 40
Study 26488941 — intervention group
Group type: COMPARATOR
Intervention: Testosterone (T) - transdermal
Number of subjects: 40
Study 26488941 — intervention group
Group type: COMPARATOR
Intervention: Testosterone (T) - undecaonate
Number of subjects: 40
Study 26488941 — intervention group
Group type: COMPARATOR
Intervention: Testosterone (T) - enantate
Number of subjects: 40
Study 24500111 — intervention group
Group type: EXPERIMENTAL
Intervention: β-alanine (BA) supplementation (6.4 g day(‐1)) for 4 weeks
Number of subjects: 40
Study 24500111 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 40
Study 23151451 — intervention group
Group type: EXPERIMENTAL
Intervention: MuStDO5 DNA vaccine with 500 μg of each plasmid and escalating doses of hGM-CSF (0, 20, 100 or 500 μg)
Number of subjects: 32
Study 23151451 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 32
Study 19570108 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotics
Number of subjects: 33
Study 19570108 — intervention group
Group type: EXPERIMENTAL
Intervention: Mood stabilizers
Number of subjects: 33
Study 19570108 — intervention group
Group type: EXPERIMENTAL
Intervention: Combinations of antipsychotics and mood stabilizers
Number of subjects: 33
Study 19570108 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 33
Study 17666974 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental breast cancer treatment
Number of subjects: 58
Study 15083253 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine
Number of subjects: 5
Study 15083253 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methylphenidate
Number of subjects: 5
Study 15083253 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 11668222 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (n = 25)
Number of subjects: 51
Study 11668222 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 26)
Number of subjects: 51
Study 9839991 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid neural network technique for segmenting and classifying dynamic contrast-enhanced MR images
Number of subjects: 0
Study 7528868 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia (MM) presentation
Number of subjects: 0
Study 7528868 — intervention group
Group type: COMPARATOR
Intervention: Paper-based text (Text) presentation
Number of subjects: 0
Study 2517282 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant portal infusion (5‐Fluorouracil 500 mg/m2/d x 7 continuous infusion + Mitomycin‐C 10 mg/m2 on day 1 as a bolus injection)
Number of subjects: 533
Study 2517282 — intervention group
Group type: COMPARATOR
Intervention: Radical surgery alone (control group)
Number of subjects: 533
Study 2517282 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-dose adjuvant chemotherapy (among 195 patients, 85%)
Number of subjects: 533
Study 2517282 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant treatment (overall)
Number of subjects: 533
Study 1166982 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin (daily doses for 21 days)
Number of subjects: 8
Study 1166982 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin plus rifampin (600 mg a day orally for the last 10 days)
Number of subjects: 8
Study 31556537 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone nasal spray 2 mg (20 mg/ml)
Number of subjects: 5
Study 31556537 — intervention group
Group type: COMPARATOR
Intervention: Intravenous naloxone 1 mg
Number of subjects: 5
Study 27865116 — intervention group
Group type: EXPERIMENTAL
Intervention: Minnesota Living with Heart Failure Questionnaire (MLHF)
Number of subjects: 0
Study 27865116 — intervention group
Group type: COMPARATOR
Intervention: EQ‐5D‐3L
Number of subjects: 0
Study 27255750 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (clinicians received electronically measured adherence report)
Number of subjects: 100
Study 27255750 — intervention group
Group type: COMPARATOR
Intervention: Control group (clinicians did not receive adherence report)
Number of subjects: 100
Study 25052792 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecstasy-related stimuli
Number of subjects: 240
Study 25052792 — intervention group
Group type: COMPARATOR
Intervention: Control stimuli
Number of subjects: 240
Study 22424843 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (Group I, n=8) administered from post-operative day 14
Number of subjects: 23
Study 22424843 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (Group II, n=15) administered at 6 months post-operatively after confirmation of endoscopic recurrence despite treatment with azathioprine, infliximab, or 5-ASA
Number of subjects: 23
Study 19416298 — intervention group
Group type: EXPERIMENTAL
Intervention: PCT-guided treatment
Number of subjects: 223
Study 19416298 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 223
Study 19416298 — intervention group
Group type: EXPERIMENTAL
Intervention: PCT-guided treatment in COPD subgroup
Number of subjects: 223
Study 19416298 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment in COPD subgroup
Number of subjects: 223
Study 17554216 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 replication capacity (RC) adjusted by baseline CD4 cell counts, HIV-1 RNA levels, and phenotypic susceptibility
Number of subjects: 139
Study 17554216 — intervention group
Group type: COMPARATOR
Intervention: HIV-1 replication capacity (RC) < or = 65%
Number of subjects: 139
Study 17554216 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 replication capacity (RC) > 65%
Number of subjects: 139
Study 17554216 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 replication capacity (RC) on a log10 basis
Number of subjects: 139
Study 17206943 — intervention group
Group type: EXPERIMENTAL
Intervention: budesonide 6 mg and ursodeoxycholic acid 15 mg/kg
Number of subjects: 77
Study 17206943 — intervention group
Group type: COMPARATOR
Intervention: ursodeoxycholic acid alone
Number of subjects: 77
Study 12447868 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha treatment
Number of subjects: 109
Study 12447868 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 109
Study 10326847 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (FK506)
Number of subjects: 35
Study 10326847 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine (CSA)
Number of subjects: 35
Study 8607150 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO (600 U/kg)
Number of subjects: 204
Study 8607150 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 204
Study 1910019 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin ointment placed on arm
Number of subjects: 26
Study 1910019 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin ointment placed on chest
Number of subjects: 26
Study 6351663 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg Mr 1268
Number of subjects: 200
Study 6351663 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg pentazocine
Number of subjects: 200
Study 6351663 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 31974081 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alteplase under current local resources
Number of subjects: 607
Study 31974081 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alteplase under assumed ideal conditions
Number of subjects: 607
Study 31974081 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy plus intravenous alteplase under assumed ideal conditions
Number of subjects: 607
Study 31974081 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventional neuroradiologists' decision to refrain from intravenous alteplase under assumed ideal conditions
Number of subjects: 607
Study 30179728 — intervention group
Group type: EXPERIMENTAL
Intervention: Criticism
Number of subjects: 97
Study 30179728 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm comments
Number of subjects: 97
Study 30179728 — intervention group
Group type: COMPARATOR
Intervention: Neutral comments
Number of subjects: 97
Study 28081827 — intervention group
Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 24902
Study 28081827 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 24902
Study 28081827 — intervention group
Group type: COMPARATOR
Intervention: GPI use
Number of subjects: 24902
Study 25887932 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydros (hyaluronan-based hydrogel suspended in hyaluronan solution)
Number of subjects: 98
Study 25887932 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydros-TA (HA plus 10 mg of triamcinolone acetonide)
Number of subjects: 98
Study 25887932 — intervention group
Group type: COMPARATOR
Intervention: Synvisc-One (hylan G-F 20)
Number of subjects: 98
Study 24075893 — intervention group
Group type: EXPERIMENTAL
Intervention: γ-T-rich supplementation (500 mg γ-T/day)
Number of subjects: 30
Study 24075893 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 30